Table 5.
Demographic data and biomarker concentrations for all cerebrospinal fluid samples
| Diagnosis | n | Sex (male/female) | Age (years) | MMSE score | Aβ1–42 (pg/ml) | Total tau (pg/ml) | Phosphorylated tau (pg/ml) | oAβ (pg/ml) | |
|---|---|---|---|---|---|---|---|---|---|
| Cohort 1 | AD | 10 | 3/7 | 72 | N/A | 442.6 ± 27.4 | 1101 ± 112.5 | 119.1 ± 8.2 | 0.9 ± 0.2 |
| (54 to 84) | (316, 568) | (609, 1,850) | (81,172) | (0.4, 2.4) | |||||
| Normal | 10 | 5/5 | 72 | N/A | 829.8 ± 57.3 | 239.5 ± 15.8 | 35.9 ± 2.1 | 0.7 ± 0.1 | |
| (62 to 81) | (607, 1,100) | (129, 315) | (26, 45) | (0.4, 1.4) | |||||
| Cohort 2 | AD | 10 | 6/4 | 72 | 18 | 184.4 ± 11.2 | 154.9 ± 22.5 | 34.4 ± 3.2 | 0.2 ± 0.0 |
| (50 to 86) | (11 to 20) | (147, 236) | (70, 247) | (22, 47) | (0.1, 0.3) | ||||
| MCI | 10 | 6/4 | 81 | 25 | 250.0 ± 25.6 | 142.3 ± 15.6 | 31.3 ± 4.3 | 0.3 ± 0.1 | |
| (76 to 89) | (23 to 28) | (165, 383) | (80, 207) | (17, 59) | (0.1, 0.8) | ||||
| Normal | 10 | 4/6 | 79 | 28 | 251.1 ± 34.1 | 58.8 ± 6.4 | 16.7 ± 1.8 | 0.2 ± 0.0 | |
| (75 to 82) | (27 to 29) | (126, 399) | (36, 84) | (10, 25) | (0, 0.4) | ||||
| Cohort 3 | MCI | 23 | 16/7 | 75 | 28 | 386.6 ± 30.0 | 152.4 ± 29.4 | 46.1 ± 5.1 | 0.9 ± 0.1 |
| (60 to 85) | (25 to 30) | (201, 599) | (39, 530) | (20, 90) | (0.3, 2.7) | ||||
| Normal | 17 | 7/10 | 70 | 29 | 475.4 ± 23.1 | 95.5 ± 20.0 | 30.7 ± 5.3 | 0.6 ± 0.1 | |
| (55 to 86) | (27 to 30) | (352, 590) | (26, 285) | (11, 77) | (0.3, 1.3) |
Data presented as mean ± standard error of the mean (range). AD, Alzheimer’s disease; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; oAβ, amyloid-beta oligomers.